Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Neovacs stock

ALNEV.PA
FR0004032746
A1CVKR

Price

0
Today +/-
-0
Today %
-0 %

Neovacs stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Neovacs stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Neovacs stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Neovacs stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Neovacs's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Neovacs Stock Price History

DateNeovacs Price
12/17/20240 undefined
12/16/20240 undefined
12/13/20240 undefined
12/12/20240 undefined
12/11/20240 undefined
12/10/20240 undefined
12/9/20240 undefined
12/6/20240 undefined
12/5/20240 undefined
12/4/20240 undefined
12/3/20240 undefined
12/2/20240 undefined
11/29/20240 undefined
11/28/20240 undefined
11/27/20240 undefined
11/26/20240 undefined
11/25/20240 undefined
11/22/20240 undefined
11/21/20240 undefined
11/20/20240 undefined
11/19/20240 undefined

Neovacs Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Neovacs, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Neovacs from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Neovacs’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Neovacs. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Neovacs’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Neovacs’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Neovacs’s growth potential.

Neovacs Revenue, EBIT and net profit per share

DateNeovacs RevenueNeovacs EBITNeovacs Net Income
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined

Neovacs Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20072008200920102011201220132014201520162017201820192020202120222023
00000000000000000
-----------------
-----------------
00000000000000000
00000000000000000
-----------------
00000000000000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Neovacs Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Neovacs is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20072008200920102011201220132014201520162017201820192020202120222023
                                 
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
                                 
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
00000000000000000
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Neovacs provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Neovacs's financial health and stability.

Assets

Neovacs's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Neovacs must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Neovacs after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Neovacs's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2007200820092010201120122013201420152016201720182019202020212022
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
----------------
0000000000000000
0000000000000000
0000000000000000
0000000000000000

Neovacs stock margins

The Neovacs margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Neovacs. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Neovacs.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Neovacs's sales revenue. A higher gross margin percentage indicates that the Neovacs retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Neovacs's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Neovacs's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Neovacs's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Neovacs. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Neovacs's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Neovacs Margin History

Neovacs Gross marginNeovacs Profit marginNeovacs EBIT marginNeovacs Profit margin
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %

Neovacs Stock Sales Revenue, EBIT, Earnings per Share

The Neovacs earnings per share therefore indicates how much revenue Neovacs has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Neovacs earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Neovacs's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Neovacs’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Neovacs's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Neovacs Revenue, EBIT and net profit per share

DateNeovacs Sales per ShareNeovacs EBIT per shareNeovacs Earnings per Share
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined

Neovacs business model

Neovacs SA is a French biotechnology company specializing in the development of immunotherapies for the treatment of autoimmune diseases and cancer. It was founded in 1993 by Pierre Vandepapeliere and is headquartered in Paris. The company has a history of groundbreaking discoveries and continuous innovation. Its business model is based on the combination of cutting-edge research and the development of customized therapies for the treatment of autoimmune diseases and cancer. Neovacs SA identifies specific proteins that trigger an immune response against the body's own cells and tissues, and develops Kinoid vaccines to neutralize these proteins and stop the autoimmune reaction. It is also specialized in the development of immunotherapies for the treatment of cancer. The main divisions of Neovacs SA are clinical development, regulatory affairs, and the manufacturing of Kinoid vaccines. It has achieved an impressive track record in the clinical development of Kinoid vaccines and collaborates with leading universities, hospitals, and research institutions to support its research and development activities. The company currently offers a range of different Kinoid vaccines for the treatment of autoimmune diseases, including a product for the treatment of lupus, a product for the treatment of rheumatoid arthritis, and a product for the treatment of chronic hepatitis B. All of these products are currently in Phase 2 development. Another important product being developed by Neovacs SA is an immunotherapeutic for the treatment of cancer. Known as TNF-Kinoid, the product aims to enhance the body's immune defense against cancer cells and inhibit tumor growth. It has shown promising results in Phase 1 clinical development and is currently in Phase 2 development. Neovacs SA is a strong and growing company in a rapidly evolving sector of biotechnology. It has an impressive track record in the clinical development of immunotherapies for the treatment of autoimmune diseases and cancer, and is well-positioned to continue making significant contributions to healthcare. Neovacs is one of the most popular companies on Eulerpool.com.

Neovacs SWOT Analysis

Strengths

1. Strong Research and Development capabilities, allowing innovation and development of new products.

2. Well-established brand reputation in the biotechnology industry.

3. Diverse and experienced workforce, contributing to the company's expertise and knowledge base.

Weaknesses

1. Reliance on a limited number of products, which increases the company's vulnerability to market fluctuations.

2. High development and production costs, impacting profitability.

3. Limited market presence and geographical reach compared to larger competitors.

Opportunities

1. Growing demand for immunotherapies, presenting opportunities for Neovacs SA to expand its product portfolio.

2. Partnerships and collaborations with larger pharmaceutical companies, enabling access to new markets and resources.

3. Emerging markets offer potential for market growth and penetration.

Threats

1. Intense competition within the biotechnology industry, from both established players and emerging startups.

2. Stringent regulations and lengthy approval processes for new products.

3. Economic uncertainties and fluctuations affecting healthcare budgets, potentially impacting product sales.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Neovacs Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Neovacs historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Neovacs shares outstanding

The number of shares was Neovacs in 2023 — This indicates how many shares 351,680 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Neovacs earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Neovacs's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Neovacs’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Neovacs's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Neovacs stock splits

In Neovacs's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Neovacs.

Neovacs shareholders

%
Name
Stocks
Change
Date
0.00377 % Neovacs SA Managers and Directors3523522/18/2024
1

Neovacs Executives and Management Board

Mr. Vincent Serra

(52)
Neovacs Chief Operating Officer, Chief Scientific Officer
Compensation 188,798

Mr. Hugo Brugiere

Neovacs Chairman of the Board, Chief Executive Officer (since 2020)
Compensation 85,000

Mr. Claude Solarz

(75)
Neovacs Director
Compensation 10,000

Mr. Baudouin Hallo

Neovacs Director
Compensation 9,000

Mr. Jean-Jacques Bertrand

(63)
Neovacs Vice Chairman of the Board (since 2003)
Compensation 6,000
1
2

Most common questions regarding Neovacs

What values and corporate philosophy does Neovacs represent?

Neovacs SA is a biotechnology company focused on developing immunotherapeutics for the treatment of autoimmune and inflammatory diseases. Their corporate philosophy centers around innovation, scientific excellence, and advancing patient care. Neovacs believes in delivering safe and effective solutions through strategic collaborations and rigorous research. By prioritizing patient well-being, Neovacs aims to bring breakthrough treatments to market that have the potential to improve the lives of individuals suffering from chronic conditions. With a strong emphasis on scientific advancement and a commitment to corporate values, Neovacs SA stands as a leader in the field of immunotherapy.

In which countries and regions is Neovacs primarily present?

Neovacs SA is primarily present in France and South Korea.

What significant milestones has the company Neovacs achieved?

Neovacs SA has achieved significant milestones in its operational history. Some notable accomplishments include the successful initiation of clinical trials for its lead product, IFNalpha-Kinoïde, which aims to treat lupus and dermatomyositis. Neovacs SA has also secured partnerships with prestigious organizations, such as the Lupus Foundation of America, enhancing its credibility in the industry. The company's innovative technology and research efforts have garnered recognition, leading to several patents being granted. Furthermore, Neovacs SA has expanded its global presence through strategic collaborations with international pharmaceutical companies, reinforcing its position as a key player in the field of immunotherapy.

What is the history and background of the company Neovacs?

Neovacs SA is a biotechnology company that specializes in developing immunotherapies for the treatment of autoimmune diseases and cancer. Founded in 1993, the company is headquartered in France. Neovacs SA focuses on leveraging its unique technology platform, Kinoids, for the production of therapeutic vaccines. These vaccines aim to stimulate the immune system to target specific antigens associated with diseases such as Lupus and Type 1 Diabetes. With a dedicated team of scientists and researchers, Neovacs SA is committed to advancing innovative treatment options and improving patient outcomes. Through its continuous efforts, the company strives to make a significant impact in the field of immunotherapy.

Who are the main competitors of Neovacs in the market?

The main competitors of Neovacs SA in the market are companies such as GlaxoSmithKline, Novartis, and Sanofi.

In which industries is Neovacs primarily active?

Neovacs SA is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Neovacs?

Neovacs SA is a biotechnology company specializing in the development of immunotherapeutic drugs. Its business model revolves around the discovery, development, and commercialization of innovative treatments for autoimmune diseases, such as lupus and dermatomyositis. By utilizing its proprietary technology, Neovacs aims to target specific proteins implicated in these diseases, ultimately offering patients safer and more effective treatment options. With a focus on advancing its pipeline of potential therapies, Neovacs aims to address significant unmet medical needs, improving the quality of life for individuals affected by autoimmune conditions.

What is the P/E ratio of Neovacs 2024?

The P/E ratio cannot be calculated for Neovacs at the moment.

What is the P/S ratio of Neovacs 2024?

The P/S cannot be calculated for Neovacs currently.

What is the Quality Investing of Neovacs?

The Quality Investing for Neovacs is 4/10.

What is the revenue of Neovacs 2024?

The revenue cannot currently be calculated for Neovacs.

How high is the profit of Neovacs 2024?

The profit cannot currently be calculated for Neovacs.

What is the business model of Neovacs

The French company Neovacs SA is a leading biotechnology company specializing in the development of immunotherapies. It is divided into several business areas, all of which contribute in different ways to the treatment of autoimmune diseases. Neovacs SA's main focus is on developing vaccines for autoimmune diseases. The main products include the IFNα-Kinoid vaccine and the VEGF-Kinoid vaccine. Both vaccines aim to reprogram the body's immune system to only attack diseased cells and spare healthy cells. Neovacs SA's IFNα-Kinoid vaccine is currently being developed for the treatment of lupus erythematosus and dermatomyositis. It is a novel therapy based on the idea that the vaccine trains the immune system of lupus patients to produce antibodies against IFNα. These antibodies block the effects of IFNα, which is responsible for harmful immune reactions in lupus patients. Neovacs SA's VEGF-Kinoid vaccine is currently being developed for the treatment of cancer. It aims to block the growth of blood vessels needed for the nourishment of tumor cells. The vaccine activates the body's immune system to specifically target the blood vessels and inhibit tumor growth. In addition to vaccine development, the company also manufactures polypeptide-based immunomodulators. These are responsible for regulating the immune system and preparing it to fight diseases. The main products in this area include the TNF-Kinoid and IL-4/IL-13 Kinoid. Both target molecules play an important role in the development of chronic inflammation associated with autoimmune diseases. Neovacs SA also has a clinical research division focused on the development of new immunotherapeutic products. Various technologies such as peptide design and antibody engineering are used to develop new medications that selectively impact the immune system. Additionally, Neovacs SA offers a wide range of services in the field of biotechnological research. This includes the development of production processes, analytical method development, and toxicity studies. Overall, Neovacs SA is a leading provider of immunotherapeutic products and services targeting the treatment of autoimmune diseases. With its wide range of products and expertise in this field, the company is well-positioned to meet future challenges in the biotechnology industry.

What is the Neovacs dividend?

Neovacs pays a dividend of 0 EUR distributed over payouts per year.

How often does Neovacs pay dividends?

The dividend cannot currently be calculated for Neovacs or the company does not pay out a dividend.

What is the Neovacs ISIN?

The ISIN of Neovacs is FR0004032746.

What is the Neovacs WKN?

The WKN of Neovacs is A1CVKR.

What is the Neovacs ticker?

The ticker of Neovacs is ALNEV.PA.

How much dividend does Neovacs pay?

Over the past 12 months, Neovacs paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neovacs is expected to pay a dividend of 0 EUR.

What is the dividend yield of Neovacs?

The current dividend yield of Neovacs is .

When does Neovacs pay dividends?

Neovacs pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Neovacs?

Neovacs paid dividends every year for the past 0 years.

What is the dividend of Neovacs?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Neovacs located?

Neovacs is assigned to the 'Health' sector.

Wann musste ich die Aktien von Neovacs kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Neovacs from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Neovacs pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Neovacs in the year 2023?

In the year 2023, Neovacs distributed 0 EUR as dividends.

In which currency does Neovacs pay out the dividend?

The dividends of Neovacs are distributed in EUR.

All fundamentals about Neovacs

Our stock analysis for Neovacs Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neovacs Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.